US 12,295,965 B2
Methods of treating sepsis using anti-sepsis lipid a (ASLA) based therapeutics
Robert K. Ernst, Silver Spring, MD (US); Erin M. Harberts, Phoenix, MD (US); and Alison J. Scott, Silver Spring, MD (US)
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US)
Filed by University of Maryland, Baltimore, Baltimore, MD (US)
Filed on Dec. 21, 2022, as Appl. No. 18/086,290.
Application 18/086,290 is a division of application No. 16/339,313, granted, now 11,633,411, previously published as PCT/US2017/055186, filed on Oct. 4, 2017.
Claims priority of provisional application 62/403,950, filed on Oct. 4, 2016.
Prior Publication US 2023/0241084 A1, Aug. 3, 2023
Int. Cl. A61K 31/7016 (2006.01); A61K 9/00 (2006.01); A61P 29/00 (2006.01); A61P 31/00 (2006.01); C07H 13/06 (2006.01); G01N 33/53 (2006.01)
CPC A61K 31/7016 (2013.01) [A61K 9/0019 (2013.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); C07H 13/06 (2013.01); G01N 33/5308 (2013.01)] 5 Claims
 
1. A method of treating and reducing the incidence and/or severity of sepsis sepsis in a subject, comprising administering to the subject an effective amount of a compound wherein the compound is selected from the group consisting of

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
and combinations thereof.